Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Status:
Terminated
Trial end date:
2017-01-30
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of lenalidomide after donor stem
cell transplant and bortezomib in treating patients with high-risk multiple myeloma. Giving
low doses of chemotherapy and total-body irradiation before a donor stem cell transplant
helps stop the growth of cancer cells. It may also the patient's immune system from rejecting
the donor's stem cells. The donated stem cells may replace the patient's immune cells and
help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the
transplanted cells from a donor can also make an immune response against the body's normal
cells. Giving a bortezomib at the time of transplant may stop this from happening. Biological
therapies, such as lenalidomide, may stimulate the immune system in different ways and stop
cancer cells from growing. Giving lenalidomide after donor stem cell transplant may be an
effective treatment for multiple myeloma.